Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H13ClN2O3S |
Molecular Weight | 276.74 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
InChI
InChIKey=RKWGIWYCVPQPMF-UHFFFAOYSA-N
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68002747
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68002747
Chlorpropamide (DIABINESE®), is a sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. It appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which chlorpropamide (DIABINESE®) lowers blood glucose during long-term administration has not been clearly established. Extra-pancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs. While chlorpropamide is a sulfonamide derivative, it is devoid of antibacterial activity. Chlorpropamide (DIABINESE®) may also prove effective in controlling certain patients who have experienced primary or secondary failure to other sulfonylurea agent.
Originator
Sources: https://patents.google.com/patent/GB853555A
Curator's Comment: # Pfizer Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096972 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22209866 |
3.04 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DIABINESE Approved UseChlorpropamide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date-3.52771211E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5053812/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORPROPAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
545 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5053812/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORPROPAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5053812/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORPROPAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >1000 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >200 uM] | ||||
yes [Inhibition 10 uM] | ||||
yes [Inhibition 10 uM] | ||||
yes [Inhibition 100 uM] | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major [Km 249.6 uM] | ||||
major [Km 584.9 uM] | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Haemolysis and agranulocytosis complicating treatment with methyldopa. | 1967 Oct 14 |
|
Pure red blood cell aplasia associated with chlorpropamide therapy. Patient summary and review of the literature. | 1969 Apr |
|
Chlorpropamide-induced immune hemolytic anemia. | 1970 Oct 22 |
|
Severe hypoglycaemic shock caused by chlorpropamide. (Case report). | 1971 Jan |
|
Inappropriate secretion of antidiuretic hormone induced by chlorpropamide. | 1972 Mar |
|
[Case of hypoglycemic coma in a female patient with diabetes insipidus treated with chlorpropamide]. | 1974 Jan-Feb |
|
Encephalopathy induced by oral hypoglycemic drugs. | 1977 Aug |
|
Tolazamide-induced cholestasis. | 1980 Aug |
|
Hypoglycemic coma, jaundice, and pure RBC aplasia following chlorpropamide therapy. | 1980 May |
|
Chlorpropamide-induced pure RBC aplasia. | 1980 May |
|
Chlorpropamide-induced haemolytic anaemia. | 1981 Jan |
|
Chlorpropamide-induced Syndrome of Inappropriate Antidiuretic Hormone Secretion. | 1981 Jul |
|
Nephrotic syndrome and immune complex glomerulonephritis associated with chlorpropamide therapy. | 1983 Feb |
|
The effect of chlorpropamide hyponatremia on mental status in a nursing home population. | 1983 May |
|
Chlorpropamide-induced hemolytic anemia. | 1984 Dec |
|
Acute hemolytic anemia associated with a chlorpropamide-induced apparent auto-anti-Jka. | 1984 May-Jun |
|
Chlorpropamide-induced cholestatic jaundice and pseudomembranous colitis. | 1985 May |
|
Chlorpropamide-induced hyponatremia in the veteran population. | 1992 Oct |
|
Hypertension secondary to chlorpropamide with amelioration by changing to insulin. | 1993 Apr |
|
Chlorpropamide-induced ADH release, hyponatremia and central pontine myelinolysis in diabetes mellitus. | 1995 Dec |
|
Correlating structure and function in ATP-sensitive K+ channels. | 1998 Jul |
|
The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. | 1999 Apr |
|
Effect of pressure up to 5.5GPa on dry powder samples of chlorpropamide form-A. | 2006 Dec 11 |
|
A new gamma-polymorph of chlorpropamide: 4-chloro-N-(propylaminocarbonyl)benzenesulfonamide. | 2007 Jun |
|
Studying the human brain anatomical network via diffusion-weighted MRI and Graph Theory. | 2008 Apr 15 |
|
A conformational polymorphic transition in the high-temperature epsilon-form of chlorpropamide on cooling: a new epsilon'-form. | 2009 Dec |
|
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. | 2009 Nov |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Sample Use Guides
The mild to moderately severe, middle-aged, stable type 2 diabetes patient should be started on 250 mg daily. In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. Older patients should be started on smaller amounts of DIABINESE®, in the range of 100 to 125 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22209866
The ATP-sensitive potassium channels containing the K23/A1369 risk haplotype were significantly less sensitive to inhibition by chlorpropamide (IC50 values for risk haplotype K23/A1369 vs. nonrisk haplotype E23/S1369 = 4.19 vs. 3.04 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA10BB02
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
||
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
||
|
WHO-ATC |
A10BB02
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
||
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
||
|
LIVERTOX |
197
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
||
|
NCI_THESAURUS |
C97936
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
||
|
NDF-RT |
N0000175608
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
||
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9020322
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
C47447
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
6801
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
Chlorpropamide
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
94-20-2
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
CHLORPROPAMIDE
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
2404
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | RxNorm | ||
|
3650
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
DB00672
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
2727
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
790
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
626720
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
1126009
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
CHEMBL498
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
100000081875
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
44634
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
WTM2C3IL2X
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
202-314-5
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
m3462
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB06209MIG
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
622
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
2051
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY | |||
|
D002747
Created by
admin on Fri Dec 15 15:21:56 UTC 2023 , Edited by admin on Fri Dec 15 15:21:56 UTC 2023
|
PRIMARY |
ACTIVE MOIETY